Clinical Trial Update: Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study [Phase 2]

View source ↗

Summary

Phase 2b, open-label rollover trial assessing the antiviral activity and safety of long-acting cabotegravir plus long-acting rilpivirine given every 2 months in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Apretude (cabotegravir) (cabotegravir)
• Edurant (rilpivirine) (rilpivirine)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2021-01-15